Prostacyclin receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Prostacyclin receptor shows approved-linked disease relevance led by pulmonary arterial hypertension. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P43119. Start with pulmonary arterial hypertension, then reuse UniProt P43119 as the stable protein anchor across project notes and exports.
Start with pulmonary arterial hypertension, then reuse UniProt P43119 as the stable protein anchor across project notes and exports.
Prostacyclin receptor shows approved-linked disease relevance led by pulmonary arterial hypertension. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.
Start review with pulmonary arterial hypertension because it currently carries approved-linked support. Linked drugs include ESUBERAPROST, ILOPROST, ILOPROST TROMETHAMINE, RALINEPAG. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProstacyclin receptor
Review this target as Prostacyclin receptor, mapped to UniProt P43119. Sequence length is 386 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostacyclin receptor as ChEMBL target CHEMBL1995, mapped to UniProt P43119. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Prostacyclin receptor is the right protein anchor across sources, using UniProt P43119 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why pulmonary arterial hypertension is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Prostacyclin receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P43119 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Prostacyclin receptor |
| UniProt Accession | P43119 |
| Component Type | Protein |
| Sequence Length | 386 aa |
Prostacyclin receptor
Review this target as Prostacyclin receptor, mapped to UniProt P43119. Sequence length is 386 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Prostacyclin receptor shows approved-linked disease relevance led by pulmonary arterial hypertension. 5 more disease programs remain visible in the same review block.
Start review with pulmonary arterial hypertension because it currently carries approved-linked support. Linked drugs include ESUBERAPROST, ILOPROST, ILOPROST TROMETHAMINE, RALINEPAG. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL494 | 9.4 | EC50 | 0.4 | Approved |
| CHEMBL495 | 8.74 | EC50 | 1.8 | Approved |
| CHEMBL1237119 | 8.72 | EC50 | 1.9 | Approved |
| CHEMBL6019262 | 8.7 | EC50 | 2.0 | Preclinical |
| CHEMBL3301604 | 8.57 | EC50 | 2.7 | Clinical |
| CHEMBL3890685 | 8.57 | EC50 | 2.7 | Preclinical |
| CHEMBL3890828 | 8.57 | EC50 | 2.7 | Preclinical |
| CHEMBL3893059 | 8.57 | EC50 | 2.7 | Preclinical |
| CHEMBL3893346 | 8.57 | EC50 | 2.7 | Preclinical |
| CHEMBL3893909 | 8.57 | EC50 | 2.7 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 76 | 40 | 6.5 |
| cell-based format | 31 | 72 | 6.3 |
| assay format | 13 | 122 | 6.7 |
| cell-free format | 2 | 12 | 6.2 |
| cell membrane format | 1 | 17 | 5.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 22 | 170 | 7.8 |
| assay format | 6 | 20 | 6.0 |
| single protein format | 3 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 3 | 6.9 |